52 results about "Hippocampal region" patented technology

The invention provides a circular RNA circ0004801 and an application of the circular RNA circ0004801 in treatment of an Alzheimer's disease. The nucleotide sequence of the circular RNA circ0004801 is as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The expression of the circular RNA circ0004801 in the hippocampal tissue of the AD mouse is obviously up-regulated, and the circular RNA circ0004801 is used as a'sponge 'of miR-7688-5p and plays a role by adjusting the TTBK1 expression and tau phosphorylation level. By knocking down the circular RNA circ0004801, the spatial learning and memory of a 3 * Tg mouse can be obviously improved, and the tau protein phosphorylation level of a hippocampus region and the NFTs density of a hippocampus DG region can be obviously reduced. Therefore, the circular RNA circ0004801 and the miR-7688-5p can be used as new targets for treating the AD (Alzheimer's disease). According to the invention, it is found for the first time that circular RNA circ0004801 regulates TTBK1 through a ceRNA mechanism, so that excessive phosphorylation of tau is driven, and a new molecular target is provided for AD early intervention treatment based on circRNA and miRNA.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention discloses armillariella mycelium polysaccharide ATMP capable of improving cognitive impairment and a preparation method and application of the armillariella mycelium polysaccharide ATMP. The polysaccharide is composed of two components, and the molecular weights of the two components are 2.30 * 10 < 4 > Da and 4.56 * 10 < 5 > Da respectively; the monosaccharide composition comprises mannose (Man), glucose (Glc) and galactose (Gal), and the molar ratio of the mannose (Man) to the glucose (Glc) to the galactose (Gal) is 1: 16.64: 1.96. Animal experiment results show that the armillariella mycelium polysaccharide ATMP can improve cognitive impairment induced by lipopolysaccharide (LPS) by improving the spatial memory ability of mice, repairing the disorder state and deletion injury of neurons in a hippocampal region and relieving neuroinflammatory response, so that the obvious neuroprotective effect is achieved. As a natural brain-benefiting active component, the armillariella tabescens mycelium polysaccharide ATMP has a wide application prospect in the related fields of brain health.

The invention discloses a traditional Chinese medicine composition for improving memory and concentration and a preparation method thereof, and relates to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12-22 parts of fructus alpiniae oxyphyllae, 15-25 parts of radix astragali, 8-16 parts of ginseng, 10-20 parts of walnuts, 10-20 parts of radix puerariae, 6-14 parts of cornel pulp, 8-18 parts of radix rehmanniae, 10-20 parts of Chinese wolfberry fruits, 15-25 parts of spina date seeds, 8-16 parts of polygala tenuifolia, 6-14 parts of rhizoma acori graminei and 4-10 parts of earthworms. According to the traditional Chinese medicine composition for improving memory and concentration and the preparation method of the traditional Chinese medicine composition, polygala ketone contained in polygala tenuifolia can specifically up-regulate hippocampal BDNF expression and doubly repair memory pathway damage caused by alcohol, volatile asarone in acorus gramineus can penetrate a blood brain barrier, and the volatile asarone is compatible with polygala tenuifolia, so that the nerve stimulation threshold value of a single component can be reduced, the intelligence promoting effect can be improved, and the traditional Chinese medicine composition can be used for improving memory and concentration. The earthworm extract can inhibit the activity of lactic dehydrogenase in the brain, and the synergistic effect mechanism of the polygala tenuifolia, the rhizoma acori graminei and the earthworm can also play a role in preventing and treating the Alzheimer's disease.

The application discloses an application of Campanula medium in treatment of perimenopausal depression, and a method is as follows: Campanula medium is added into 10 times of distilled water in weight, decocted for 1 h and filtered, residues are added with 8 times of distilled water, and then decocted for 1 h and filtered, and filtrates are combined, and concentrated into 1 g / mL of medicinal liquid according to medicinal material, so that Campanula medium medicinal liquid is obtained. According to the experimental result, Campanula medium can improve the depression and anxiety behavior of PMD model mice. Campanula medium can improve the hippocampus tissue morphology and structure of the PMD model mice, increase the neuron Nissl body abundance of the hippocampus, promote the ER-BDNF-TrkB path, improve the monoamine neurotransmitter level, correct the HPA axis hyperactivity, and thus improve the depression behavior.

This invention discloses a method for identifying and processing abnormal hippocampal atrophy in functional MRI images of the brain, comprising: acquiring functional MRI image data of the brain to be processed; preprocessing the functional MRI image data of the brain to obtain preprocessed functional MRI image data of the brain; extracting the hippocampal region from the preprocessed functional MRI image data of the brain; constructing a three-dimensional image of the hippocampus based on the hippocampal region; performing feature extraction on the three-dimensional image of the hippocampal region based on a deep learning network to obtain feature extraction results; and classifying and identifying abnormal atrophy of the hippocampal region according to the feature extraction results to obtain classification and identification results.

This invention discloses the application of burdock root polysaccharide in the preparation of drugs for treating cognitive impairment, belonging to the field of traditional Chinese medicine technology. Experiments demonstrate that burdock root polysaccharide can improve cognitive impairment and independent exploration ability in D-galactose-induced cognitive impairment model mice, increase superoxide dismutase activity in mouse serum, reduce malondialdehyde content, decrease the content of interleukin-1β and tumor necrosis factor-α in the hippocampus of mouse brains, and alleviate the loss of neurons in the hippocampus of cognitive impairment model mice, thereby achieving a neuroprotective effect and demonstrating a good therapeutic effect on cognitive impairment. This provides a new approach for developing drugs related to the treatment of cognitive impairment.

The invention relates to an exosome for targeting a central nervous system delivery reagent. Protein for targeting the central nervous system on the exosome is one or more of membrane protein SIRP alpha, membrane protein MCAM and active fragments thereof. The exosome can efficiently target a central nervous system, can target a hippocampal region and a hypothalamic region, can deliver bioactive substances to the center and exert functions, and has good biocompatibility and biological safety.

The invention relates to Witzia ciliaris capable of regulating mood health and relieving anxiety and an application of the Witzia ciliaris. The Witzia ciliaris is separated from a healthy human excrement sample. According to the present invention, the Witzia ciliata KY009 can regulate the levels of 5-hydroxytryptamine, brain-derived neurotrophic factors and cortisol so as to provide the anti-depression effect, can significantly reduce the contents of hippocampal proinflammatory factors such as IL-1beta, IL-6 and IFN-alpha, and has the neuroinflammation inhibition activity. The strain and the composition thereof can be used for preparing medicines for treating depression, functional foods for relieving depressive mood and health-care products for improving mood, play a therapeutic role by correcting immune imbalance state of a body and regulating neuroinflammation, and provide a new microbial intervention strategy for treatment of depression and related mood disorders.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

The invention discloses an N-methyl-D-aspartic acid receptor NR2B subunit interference peptide and an application of the N-methyl-D-aspartic acid receptor NR2B subunit interference peptide. Through reasonable design and synthesis, the interference peptide can be specifically combined with endogenous neurotoxic metabolite quinolinic acid (QA), and the combination between the QA and NR2B is blocked in a competitive mode, so that the NR2B-mediated excitatory neurotoxic reaction is selectively inhibited. The polypeptide can remarkably reverse neuron damage and shows an excellent nerve protection effect. In an obesity-related cognitive impairment model and an Alzheimer's disease mouse model, the interference peptide recovers neuronal synaptic injury in a hippocampus region by blocking a QA-NR2B signal channel, effectively improves cognitive hypofunction, and provides an innovative intervention strategy for prevention and treatment of neurodegenerative diseases.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD73 positive NK cells of umbilical cord blood from different starting sources and application of the CD73 positive NK cells to treatment of Alzheimer's disease. The CD73 + NK cells differentiated from different initial cell types (CD34 positive cells, CD3 negative / CD56 positive cells and CD56 negative cells) of umbilical cord blood are studied, it is found that all the initial cell types of umbilical cord blood sources can be differentiated into the CD73 + NK cells, 34 +-73-NK cells show a higher growth rate, 56-73-NK cells show higher cytotoxicity, and the CD73 + NK cells can be differentiated into the CD73 + NK cells. And the overall effect of the 56-73-NK cell is superior to that of the 34 < + >-73-NK cell. Further research shows that the CD73 + NK can inhibit activation of STZ injection mouse hippocampal microglia and astroglia, so that the neuroinflammation of the hippocampal is reduced, and a new solution is expected to be provided for treatment of AD.

The invention discloses a composite microneedle with bacterial outer membrane vesicles loaded with active ingredients as well as a preparation method and application of the composite microneedle. The composite microneedle is prepared from the bacterial outer membrane vesicles and the active ingredients loaded in the bacterial outer membrane vesicles, the bacterial outer membrane vesicles are derived from mucus eubacterium, the active ingredient is cycloastragenol, and the composite microneedle has a transdermal delivery function and delivers the active ingredient to a target tissue in a targeted manner. The method comprises the following steps: firstly, encapsulating cycloastragenol into mucus eubacterium outer membrane vesicles through a co-incubation or active drug loading technology to form a composite nano-carrier; the EL-OMVs-CAG compound prepared by the invention has good biocompatibility and blood brain barrier penetrating ability, and can target a central nervous system, regulate the activity of microglial cells, inhibit neuroinflammatory response and reduce synaptic loss and neuronal apoptosis in a hippocampal region, so that cognitive function impairment caused by operation and anesthesia is improved.

The invention discloses application of alpha-cyperone in preparation of drugs for treating sepsis, a mouse sepsis model is constructed by adopting a cecum ligation perforation (CLP) method, and through sepsis symptom clinical scoring and open field experiments, it is found that alpha-cyperone reverses the sepsis symptom, recovers the weight of a mouse and reduces the death rate of the mouse; through a Q-PCR (Quantitative Polymerase Chain Reaction) method, a Western Blot method and the like, the alpha-cyperone is found to alleviate oxidative stress and cell inflammatory factor expression, alleviate brain synaptic dysfunction and alleviate nerve cell pyroptosis in a hippocampus area; animal experiments find that alpha-cyperone has the function of improving sepsis-related encephalopathy, and in a word, a new way is provided for sepsis treatment.

The invention relates to the technical field of Gaucher disease treatment, in particular to application of nicotine in preparation of drugs for relieving, adjuvant therapy or treatment of Gaucher diseases. The invention reveals for the first time that nicotine can enhance mitochondrial autophagy mediated by a PGC1 alpha / Parkin pathway by reducing accumulation of glucosylceramide and up-regulating protein expression of PGC1 alpha and Synaptophysin in a hippocampal region, also improves synaptic function and various neurotransmitter levels, enhances learning memory and application ability, and further improves neurodegenerative diseases caused by Gaucher disease.

The invention belongs to the technical field of biological medicine, and discloses a safe and efficient non-gene editing neural stem cell and application thereof in treatment of nervous system related diseases. The invention provides a non-gene-edited neural stem cell (hCiPSC-NSCs) derived from human induced pluripotent stem cells, the neural stem cell is obtained by reprogramming human umbilical cord mesenchymal stem cells through a small molecule compound (such as a TGF-beta / GSK-3beta inhibitor), exogenous gene introduction is not involved, and the neural stem cell has a normal karyotype, no tumorigenicity and relatively high safety; and the efficient implantation of the non-tumorigenicity hippocampal region is realized in three months. The neural stem cell can improve the autism-like phenotype of a VPA-exposed rat by targeting the intestinal-brain axis at the same time.

The invention relates to application of an exosome derived from olfactory mucosa mesenchymal stem cells pretreated based on active peptide in improvement of neuroinflammation, in particular to a treatment strategy for neuroinflammation of Alzheimer's disease (AD). An IFN-FGF fusion protein (SEQ ID NO: 3) and a coding gene (SEQ ID NO: 4) of the IFN-FGF fusion protein are constructed, and the IFN-FGF fusion protein and the coding gene (SEQ ID NO: 4) are used for in-vitro pretreatment of OM-MSCs, so that the A-MS Cs-Exo exosome with anti-inflammatory and neuroprotective functions is obtained. In an A beta oligomer-induced AD neuroinflammation model, the A-MSCs-Exo significantly alleviates neuroinflammation and cognitive impairment by inhibiting excessive activation of hippocampal Iba1 + microglia cells, reducing serum IL-6 level, improving SOD activity and improving Morris water maze behavioral performance, the effect is better than that of traditional FGF-1 pretreatment (B-MSCs-Exo) and untreated exosome (C-MSCs-Exo), and the A-MSCs-Exo can be used for preparing the A beta oligomer-induced AD neuroinflammation model. The invention provides a novel exosome intervention strategy for AD treatment.

The invention discloses Weissella sinus PD13 for improving Alzheimer's disease and application of the Weissella sinus PD13, and relates to the technical field of biological medicine. Experiments prove that Weissella cibaria PD13 can improve spatial learning and memory impairment and autonomous exploration ability of AD model mice in Alzheimer's disease model mice induced by brain injection of A beta oligomer, and alleviate damage of neurons in hippocampal regions of the Alzheimer's disease model mice, so that the effect of protecting neurons is achieved, and the Weissella cibaria PD13 can be used for preparing drugs for treating Alzheimer's disease. According to the present invention, the Weissella cibaricola can effectively prevent and treat the Alzheimer's disease, increase the glutathione content and the superoxide dismutase enzyme activity of the mouse serum, and reduce the malondialdehyde content, such that the Weissella cibaricola has good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.

The invention provides application of a probiotic-fructo-oligosaccharide-lycium ruthenicum microecological preparation for targeted hippocampal neuron repair in neuroprotection and a composite product, and relates to the technical field of microorganisms. The probiotic oligosaccharide composition provided by the invention comprises lycium ruthenicum powder, fructo-oligosaccharide and compound probiotic powder, the compound probiotic powder comprises plant lactobacillus, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis, and the probiotic composition provided by the invention can significantly improve the neuron morphology and arrangement of a hippocampus area of a model group; the neuron damage is reduced.

The invention relates to a targeted central nervous system engineered exosome capable of efficiently enriching RNAi as well as a preparation method and application of the targeted central nervous system engineered exosome. The invention particularly relates to a sorting signal for regulating and controlling RNAi to be enriched into the exosome, and the RNAi enriched into the exosome through the sorting signal can be effectively combined with beta-amyloid protein mRNA expressed in a central nervous system after reaching a cortex and a hippocampal region. The invention also relates to a chimera comprising the sorting signal and the RNAi, and an exosome enriched with the RNAi. The exosome can efficiently target a central nervous system through overexpressed SIRP alpha and MCAM, and the contained siRNA can inhibit the production of beta-amyloid protein mRNA.

The invention discloses an AD rat model imaging experiment method, a QSM graph construction method and QSM application, which can be used for researching pathological protein change in a hippocampus area. The rat model imaging experiment method comprises the following steps: (I) respectively injecting equal amounts of A [beta] 1-40 and PBS solutions into hippocampus CA1 regions on two sides of an SD rat to construct an A [beta]-induced AD rat model G1 and a control group G2; (II) replacing an A beta sequence in a rat App gene and mutation sites around the A beta sequence with a human source sequence; (III) evaluating the spatial orientation learning and memory ability of the rat by using a Morris water maze experiment which is carried out for 6 days in total and is divided into two stages: the first stage is a platform hiding stage test for 5 days; and the second stage is a platform-free space exploration stage test for one day.

The present invention relates to uses of regulatory T cells manipulated to overexpress CX3CR1. The regulatory T cells induced to overexpress CX3CR1 according to the present invention reduce microglial activation in an LPS-induced neuroinflammation animal model and suppress immune inflammatory responses of activated microglia by inhibiting the expression of pro-inflammatory markers and cytokines in the cortical and hippocampal regions of the brain, and thus can be used for reducing microglial activation or for treating neuroinflammatory diseases or neurodegenerative diseases caused by hyperactivation of microglia in the brain.

The application provides a robot positioning mapping method based on a visual cortex and hippocampus space coding, and the method comprises the following steps: acquiring linear velocity and angular velocity through a wheel encoder and an inertial measurement unit, and obtaining robot pose information through path integration; collecting scene images by using a camera and extracting GIST features, obtaining a winning cell in a view cell network through Euclidean distance matching, updating weights, and introducing a posteriori entropy adaptive threshold to perform robust scene matching; storing the pose information and the successfully matched weight vector into a hippocampus CA1 area location cell, eliminating cumulative errors through iterative optimization, controlling the map size through space density redundancy pruning, and adopting a hierarchical switching strategy to perform scale stretching optimization, so that fast mapping is realized. Through simulating a biological space coding mechanism, the application improves scene recognition robustness, positioning consistency and mapping efficiency, and is suitable for intelligent navigation of a mobile robot.

The present disclosure relates to the field of biomedicine, and discloses a nutritional composition for intervention or treatment of autism and a preparation method thereof, aiming to solve the problems of safety, compliance and insufficient targeting mechanism of existing intervention programs for social impairment of autism. The composition comprises leucine, isoleucine and valine in a molar ratio of 1:1:1, with a total concentration of 0.753 mg / kg of body weight, in the form of oral liquid, and a pH of 6.87.4. The preparation method comprises weighing the amino acids according to the molar ratio, dissolving them in 0.9% sodium chloride injection, filtering, dispensing and sealing. The present application can safely and effectively improve the social impairment of autism patients and plays a role by up-regulating the expression of MyT1L in the hippocampus.

The invention discloses a wireless micro-magnetic stimulation device based on magnetic coupling resonance, and belongs to the technical field of biomedical engineering. Aiming at the problems of limited application scene and inconvenient operation caused by wired power supply of a traditional micro-magnetic stimulation device, the invention designs a wireless micro-magnetic stimulation device by combining a magnetic coupling resonance wireless energy transmission technology and a micro-magnetic stimulation nerve regulation and control technology. According to the device, a magnetic coupling resonance model is established through theoretical analysis, the coil structure and the circuit design are optimized, and the wireless energy transmission efficiency and stability are improved. The device adopts a self-made transmitting terminal copper wire coil and a stimulation front end made of a flexible circuit board, and is suitable for in-vitro and short-term in-vivo experiments through waterproof and biocompatibility design. Simulation analysis and hippocampal brain slice in-vitro experiments prove that the device can accurately regulate and control deep nerve nuclei of the brain, has a remarkable promotion effect on LTP in a hippocampal Schaffer-CA1 region, and can be used for neuroscience research and nervous system disease treatment.

The present application relates to a pharmaceutical composition for treating chronic pain and pain-related memory impairment diseases, and belongs to the technical field of biological medicine. Through animal experiments, it is confirmed that the expression of C3 in the hippocampal area of chronic pain mice is increased, and exogenous C3 injection can induce pain and memory impairment phenotype. The present application proposes to use C3-C3aR inhibitors, such as small molecule inhibitor SB290157, to block the pathway. The pharmaceutical composition can be administered by systemic injection or targeted brain region administration to achieve intervention. C3aR inhibitors can simultaneously improve pain behavior and memory function in SNI model mice. By regulating the C3-C3aR signaling pathway in the hippocampal area, the present application directly acts on the pathological core link of pain-memory comorbidity, and provides a small molecule targeted treatment path for chronic pain patients.

The invention discloses an application of polypeptide in preparation of antidepressant drugs, and belongs to the field of biological medicine, the polypeptide is neuropeptide PEN or a functional fragment and a derivative thereof, and the PEN is one of a plurality of derivative peptides formed by cutting a protein precursor proSAAS existing in a central nervous system of a mammal through proprotein convertase. Research finds that PEN as an endogenous polypeptide can significantly shorten the immobility time of a mouse in a tail suspension experiment and a forced swimming experiment and improve the depression-like behavior of the mouse, shows an obvious anti-depression effect, and has no obvious influence on the movement function of the mouse. A further research result shows that the anti-depression mechanism of PEN is related to inhibition of NMDAR2B / CaMKII signals of a mouse hippocampus and increase of ERK1 / 2 protein activity of the hippocampus. The invention discovers potential application of PEN in preparation of antidepressant drugs for the first time, and provides a new target and theoretical basis for development of novel, safe and effective antidepressant drugs.

The application relates to a system and method for treating Alzheimer's disease, and belongs to the field of medical devices. The system comprises a multi-modal data acquisition module, an individualized simulation navigation module, a precise signal generation and driving module, and a closed-loop feedback control module. The system constructs an individual head model through finite element analysis to optimize electrode distribution, generates an interference envelope in the hippocampus area by using two high-frequency currents, and realizes closed-loop adjustment of parameters by combining a repeated continuous mode and physiological feedback. The application realizes non-invasive and accurate regulation of a deep target point, significantly improves hippocampal oscillation synchronization and synaptic plasticity, improves the memory of patients, reduces the activation of the surface cortex, and has good clinical safety.

The application discloses an olfactory training system for activating a motor-olfactory-hippocampal neural network and application, the system comprises a plurality of different odor sources, the odor source is used for alternating olfactory stimulation to stroke patients, so as to improve the cognitive function and / or olfactory function of the patient. The application firstly discloses that the function connection of the motor-olfactory-cognitive brain area is disordered after stroke, the function of the VIP neuron of the motor cortex (MO) around the infarction is inhibited; the VIP neuron of the MO region dominates the GABA neuron of the dorsal peripeduncular area (DP) through an inhibitory pathway, activating the pathway can remove the inhibition of the glutamatergic pyramidal neuron of the DP, enhance the excitatory input to the hippocampal CA3 region, and restore the olfaction and spatial memory. The application proves that the structured olfactory training can activate the loop, and significantly improve the cognitive function of the stroke patient. The application provides a simple and non-invasive stroke rehabilitation strategy.

This invention discloses an implantable medical device comprising a polyethylene glycol diacrylate hydrogel matrix and monodisperse guanine peptide nucleic acid self-assembled microspheres immobilized within the polyethylene glycol diacrylate hydrogel matrix. The guanine peptide nucleic acid self-assembled microspheres exhibit a spatial quasi-periodic distribution within the hydrogel matrix characterized by short-range order and long-range disorder. This implantable medical device combines the light-harvesting advantages of biomimetic structures, the wide bandgap photoelectric properties of bio-organic semiconductors, and the flexible tissue integration capabilities of hydrogels to obtain an amorphous photonic crystal material with programmable optical properties and wide bandgap semiconductor properties. This product aims to achieve efficient, stable, and biosafe neurophotomodulation and, through mechanisms such as enhancing cortical gamma oscillations, effectively activating disease-related microglia in the hippocampus, and promoting the clearance of β-amyloid plaques, provides a novel, non-genetic, implantable optical therapy strategy for neurodegenerative diseases.